Project description
Elana Heart Bypass to Revolutionize Coronary Artery Bypass Grafting
Coronary Artery Bypass Grafting (CABG) is used to treat severe coronary artery disease, and prevents myocardial infarction (heart attack). Performed on an arrested (non-beating) heart and via a large incision, this procedure is highly invasive. The ELANA Heart Bypass system enables minimally invasive CABG via a laser-assisted procedure on the beating heart without opening the chest. This directly impels shorter recovery and less complications for the patients. The EU-funded SAFE-CAB project plans to accelerate the time to market of this product through final clinical validation and regulatory certification. Their goal is to replace invasive CABG with the ELANA Heart Bypass, as the new standard of care. Minimally invasive CABG could significantly reduce recovery times, complications, and hospital costs. Being the new standard of care, the ELANA Heart Bypass could dramatically improve patient outcomes.
Objective
Coronary Artery Bypass (CAB) surgery is performed annually in >700,000 patients to treat coronary artery disease and
prevent myocardial infarction (heart attack). Standard CAB surgery involves a highly invasive open-heart procedure in
arrested/non-beating heart, that is associated with long recovery times and severe complications. The surgeons are seeking
for less invasive, closed chest CAB procedures on beating heart, but current solutions are technically extremely challenging and thereby
only used in <1-3% of all surgeries. The vision of the SAFE-CAB consortium is to make the minimally invasive CAB
surgeries available to all surgeons as a novel standard of care, thereby substantially improve patient outcomes and reduce
health care costs. The goal of the project is to bring to market a first-of-its-kind laser-assisted minimally invasive surgical
system (surgical kit containing surgical implant and laser catheter). SAFE-CAB enables minimally invasive procedure on
beating heart, without the need for arresting blood flow or complex hand suturing. With shorter recovery times, less
complications and improved survival rates in high-risk patients, the SAFE-CAB technology has a potential to replace high-risk
open-heart surgeries. Replacing only 15% of open-heart surgeries in Europe and US translates to annual
market opportunity of >€89M and >€192M. Dutch SME AMT Medical has developed the proprietary SAFE-CAB
technology to clinical readiness. To substantially accelerate the market entry of the product, the company partners with a leading European cardiac surgery hospital Deutsches Herzzentrum Berlin and a pan-European clinical/regulatory medical device company HEMEX to
obtain regulatory approval through final clinical validation . To realize European wide-implementation, the consortium is complemented by a surgery training company LifeTec Group and the oldest professional organisation for cardiac surgeons European Society of CardioVascular and Endovascular Surgery.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- medical and health sciences clinical medicine surgery
- medical and health sciences clinical medicine cardiology cardiovascular diseases
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EC - Horizon 2020 Framework Programme
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.3. - PRIORITY 'Societal challenges
See all projects funded under this programme -
H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
IA - Innovation action
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-FTI-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
3584 CM Utrecht
Netherlands
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.